Valuation: Armata Pharmaceuticals, Inc.

Market Cap 12Cr 11Cr 9.82Cr 8.88Cr 17Cr 1.12TCr 17Cr 117.69Cr 46Cr 590.18Cr 45Cr 44Cr 1.88TCr P/E 2026 *
-1.72x
P/E 2027 * -2.21x
Enterprise Value 12Cr 11Cr 9.82Cr 8.88Cr 17Cr 1.12TCr 17Cr 117.69Cr 46Cr 590.18Cr 45Cr 44Cr 1.88TCr EV / Sales 2026 *
28x
EV / Sales 2027 * 43.3x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day-4.69%
1 week+9.71%
Current month-16.89%
1 month-28.40%
3 months-40.89%
6 months-79.39%
Current year-51.43%
1 week 2.83
Extreme 2.83
3.42
1 month 2.74
Extreme 2.745
4.56
Current year 2.74
Extreme 2.745
14.98
1 year 2.74
Extreme 2.745
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 11/07/2023
Director of Finance/CFO 42 16/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 09/05/2019
Director/Board Member 66 12/02/2020
Director/Board Member 51 12/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/07/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/04/26 Free

Director

51,280 0.1400%
14/03/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
-3.12%+9.71%-12.10%+44.55% 12Cr
-0.21%-6.36%+49.00%+74.13% 6.63TCr
-0.22%+6.53%+11.68%+90.35% 5.29TCr
+0.82%+5.41%+8.05%+74.45% 5.48TCr
+2.67%+4.96%+25.76%+49.69% 4.41TCr
+0.93%+10.52%+23.03%+130.22% 4.37TCr
-0.49%+1.21%+266.16%+967.07% 4.21TCr
+0.10%+9.96%+17.15%+59.33% 3.4TCr
-1.30%-3.61%+37.37%+7.16% 2.62TCr
+0.69%+5.60%+36.60%+26.39% 2.34TCr
Average -0.19%+4.62%+46.27%+152.33% 3.88TCr
Weighted average by Cap. +0.33%+4.67%+51.80%+168.28%

Financials

2026 *2027 *
Net sales 42.5L 37.87L 35.06L 31.73L 59.78L 40Cr 60.49L 4.2Cr 1.65Cr 21Cr 1.59Cr 1.56Cr 67Cr 27.5L 24.51L 22.69L 20.53L 38.68L 26Cr 39.14L 2.72Cr 1.07Cr 14Cr 1.03Cr 1.01Cr 43Cr
Net income -7.66Cr -6.83Cr -6.32Cr -5.72Cr -11Cr -722.85Cr -11Cr -76Cr -30Cr -379.95Cr -29Cr -28Cr -1.21TCr -7.2Cr -6.42Cr -5.94Cr -5.38Cr -10Cr -679.44Cr -10Cr -71Cr -28Cr -357.14Cr -27Cr -26Cr -1.14TCr
Net Debt - -
Projected Income Statement - Annual - Armata Pharmaceuticals, Inc.
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
22/26/22 $3.060 -4.38% 93,554
20/26/20 $3.200 +4.23% 87,387
19/26/19 $3.070 -8.90% 88,261
16/26/16 $3.370 +9.06% 1,54,319
15/26/15 $3.090 +11.15% 1,15,784
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Armata Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.200USD
Average target price
17.50USD
Spread / Average Target
+446.88%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Armata Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ARMP Stock